As a result of these considerations, aim of our study was to compare the two different “safe” GH cut-off values which were proposed in literature, both as GH profile and single fasting GH, about their reliability in defining treatment control in acromegaly patients under somatostatin receptor ligands (SRLs) therapy. Here, GH1 is linked to acromegaly.